Richard J. Hodes

Richard J. Hodes

Auto-generated profile, based on publicly available information

Richard J. Hodes

Affiliations National Cancer Institute (NCI), National Institutes of Health (NIH), Experimental Immunology Branch, Bethesda, MD, United States of America, National Institute on Aging (NIA), NIH, Bethesda, MD, United States of America

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2002 in Nature Reviews Immunology
Verified
Journal Article
Closed access
RHRichard J. Hodes
Richard J. Hodes
KHKaren S. Hathcock
Karen S. Hathcock
NWNan-Ping Weng
Nan-Ping Weng

3 November 2008 in Epigenetics & Chromatin
Verified
Journal Article
Open access
PDF file
ANAsako J Nakamura
Asako J Nakamura
YCY Jeffrey Chiang
Y Jeffrey Chiang
KHKaren S Hathcock
Karen S Hathcock
Izumi HorikawaIzumi Horikawa
Izumi Horikawa
OSOlga A Sedelnikova
Olga A Sedelnikova
WBWilliam M Bonner
William M Bonner
Cellular senescence is a state reached by normal mammalian cells after a finite number of cell divisions and is characterized by morphological and physiological changes including terminal cell-cycle arrest. The limits on cell division imposed by senescence may play an important role in both organismal aging and in preventing tumorigenesis. Cellular senescence and organismal aging are both accompanied by increased DNA damage, seen as the formation of γ-H2AX foci (γ-foci), which may be found on uncapped telomeres or at non-telomeric sites of DNA damage. However, the relative importance of telomere- and non-telomere-associated DNA damage to inducing senescence has never been demonstrated. Here we present a new approach to determine accurately the chromosomal location of γ-foci and quantify the number of telomeric versus non-telomeric γ-foci associated with senescence in both human and mouse cells. This approach enables researchers to obtain accurate values and to avoid various possible misestimates inherent in earlier methods.

1 October 1988 in Nature
Verified
Journal Article
Closed access
RARyo Abe
Ryo Abe
MVMelanie S. Vacchio
Melanie S. Vacchio
BFBarbara Fox
Barbara Fox
RHRichard J. Hodes
Richard J. Hodes

1 January 2007 in Journal of Immunotherapy
Verified
Journal Article
Closed access
XSXinglei Shen
Xinglei Shen
JZJuhua Zhou
Juhua Zhou
KHKaren S. Hathcock
Karen S. Hathcock
PRPaul Robbins
Paul Robbins
DPDaniel J. Jr Powell
Daniel J. Jr Powell
RHRichard J. Hodes
Richard J. Hodes
Transfer of autologous tumor-specific tumor infiltrating lymphocytes (TILs) in adoptive immunotherapy can mediate the regression of tumor in patients with metastatic melanoma. In this procedure, TILs from resected tumors are expanded in vitro, then administered to patients and further stimulated to proliferate in vivo by the administration of high dose IL-2. After in vitro expansion, TILs are often dominated by a few specific clonotypes, and recently it was reported that the persistence in vivo of one or more of these clonotypes correlated with positive therapeutic response. We and others have previously shown that repeated in vitro stimulation and clonal expansion of normal human T lymphocytes results in progressive decrease in telomerase activity and shortening of telomeres, ultimately resulting in replicative senescence. In the studies reported here, we therefore compared telomerase activity and telomere length in persistent and nonpersistent TIL clonotypes before transfer in vivo, and found a correlation between telomere length and clonal persistence. We also observed that TILs proliferate extensively in vivo in the days after transfer, but fail to induce substantial telomerase activity, and undergo rapid decreases in telomere length within days after transfer. Thus, in vivo loss of telomeres by clonotypes that have the shortest telomeres at the time of administration may drive these clones to replicative senescence, whereas cells with longer telomeres are able to persist and mediate antitumor effects. These findings are relevant both to predicting effectiveness of adoptive immunotherapy and in deriving strategies for improving effectiveness by sustaining telomere length.

1 May 2014 in Immunity
Verified
Journal Article
Closed access
MWMasashi Watanabe
Masashi Watanabe
KMKyung Duk Moon
Kyung Duk Moon
MVMelanie S. Vacchio
Melanie S. Vacchio
KHKaren S. Hathcock
Karen S. Hathcock
RHRichard J. Hodes
Richard J. Hodes

19 March 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KHKaren S. Hathcock
Karen S. Hathcock
MHMichael T. Hemann
Michael T. Hemann
KOKay Keyer Opperman
Kay Keyer Opperman
MSMargaret A. Strong
Margaret A. Strong
CGCarol W. Greider
Carol W. Greider
RHRichard J. Hodes
Richard J. Hodes
Telomeres are usually maintained about an equilibrium length, and the set point for this equilibrium differs between species and between strains of a given species. To examine the requirement for telomerase in mediating establishment of a new telomere length equilibrium, we generated interspecies crosses with telomerase mTR knockout mice. In crosses between C57BL/6J (B6) and either of two unrelated mouse species, CAST/Ei and SPRET/Ei, telomerase mediated establishment of a new telomere length equilibrium in wild-type mTR+/+mice. This new equilibrium was characterized by elongation of the short telomeres of CAST/Ei or SPRET/Ei origin. In contrast, mTR−/−offspring of interspecies crosses failed to elongate telomeres. Unexpectedly, haploinsufficiency was observed in mTR+/−heterozygous interspecies mice, which had an impaired ability to elongate short SPRET/Ei or CAST/Ei telomeres to the new equilibrium set point that was achieved in wild-type mTR+/+mice. These results demonstrate that elongation of telomeres to a new telomere set point requires telomerase and indicate that telomerase RNA may be limitingin vivo.